<DOC>
	<DOC>NCT02310269</DOC>
	<brief_summary>This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.</brief_summary>
	<brief_title>Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<criteria>Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry Patients with ectopic ACTHdependent Cushing's syndrome Patients with adrenal Cushing's syndrome Patients with Pseudo Cushing's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cushing's disease,</keyword>
	<keyword>pasireotide s.c.</keyword>
	<keyword>Signifor</keyword>
</DOC>